Literature DB >> 20182347

MUM1/IRF4: A Review.

Gabriela Gualco1, Lawrence M Weiss, Carlos E Bacchi.   

Abstract

MUM1/IRF4 protein is a member of the interferon regulatory factor (IRF) family of transcriptional factors initially described as downstream regulators of interferon signaling. The quantity of this factor varies within the hematopoietic system in a lineage and stage-specific way. It is considered to be a key regulator of several steps in lymphoid, myeloid, and dendritic cell differentiation and maturation. MUM1/IRF4 expression is observed in many lymphoid and myeloid malignancies, and may be a promising target for the treatment of some of these neoplasms. We reviewed the literature on MUM1/IRF4, with emphasis on the pathologic aspects of this marker in reactive and malignant hematologic and nonhematologic conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182347     DOI: 10.1097/PAI.0b013e3181cf1126

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  22 in total

1.  Interferon regulatory factor 4 is activated through c-Src-mediated tyrosine phosphorylation in virus-transformed cells.

Authors:  Ling Wang; Shunbin Ning
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

2.  Peripheral T-cell lymphoma with t(6;14)(p25;q11.2) translocation presenting with massive splenomegaly.

Authors:  Joan Somja; Bettina Bisig; Christophe Bonnet; Christian Herens; Reiner Siebert; Laurence de Leval
Journal:  Virchows Arch       Date:  2014-03-07       Impact factor: 4.064

3.  Expression of IRF-4 and IBP in skin lesions of patients with psoriasis vulgaris.

Authors:  Anhong Ni; Hongxiang Chen; Yan Wu; Wen Li; Shanjuan Chen; Jiawen Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

4.  MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.

Authors:  Z Xie; C Bi; J Y Chooi; Z L Chan; N Mustafa; W J Chng
Journal:  Leukemia       Date:  2015-06-30       Impact factor: 11.528

5.  Role of selected genetic variants in lung cancer risk in African Americans.

Authors:  Margaret R Spitz; Christopher I Amos; Susan Land; Xifeng Wu; Qiong Dong; Angela S Wenzlaff; Ann G Schwartz
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

6.  IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.

Authors:  Sensen Zhang; Jiaren Xu; Shuang Wu; Rong Wang; Xiaoyan Qu; Wenjun Yu; Jiangyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2013-05-12       Impact factor: 3.064

Review 7.  [B-cell neoplasms with plasmacellular and plasmablastic differentiation].

Authors:  F Fend; L Quintanilla-Martínez
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

8.  Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand.

Authors:  Tawatchai Pongpruttipan; Tanawan Kummalue; Anan Bedavanija; Archrob Khuhapinant; Koichi Ohshima; Fumiko Arakawa; Daisuke Niino; Sanya Sukpanichnant
Journal:  Diagn Pathol       Date:  2011-08-25       Impact factor: 2.644

9.  MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma.

Authors:  Wiyada Kwanhian; Dido Lenze; Julia Alles; Natalie Motsch; Stephanie Barth; Celina Döll; Jochen Imig; Michael Hummel; Marianne Tinguely; Pankaj Trivedi; Viraphong Lulitanond; Gunter Meister; Christoph Renner; Friedrich A Grässer
Journal:  Cancer Med       Date:  2012-09-18       Impact factor: 4.452

10.  IRF4 is a novel mediator for neuronal survival in ischaemic stroke.

Authors:  S Guo; Z-Z Li; D-S Jiang; Y Y Lu; Y Liu; L Gao; S-M Zhang; H Lei; L-H Zhu; X-D Zhang; D-P Liu; H Li
Journal:  Cell Death Differ       Date:  2014-02-07       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.